<DOC>
	<DOCNO>NCT00006243</DOCNO>
	<brief_summary>This randomize pilot clinical trial study vaccine therapy sargramostim treat patient stage IV malignant melanoma . Vaccines make melanoma peptide antigen may help body build effective immune response kill tumor cell . Colony-stimulating factor , sargramostim , increase number white blood cell platelets find bone marrow peripheral blood . Giving vaccine therapy together sargramostim may effective treatment malignant melanoma</brief_summary>
	<brief_title>Vaccine Therapy Sargramostim Treating Patients With Stage IV Malignant Melanoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine immunological effect immunization protocol utilize MART-1:27-35 ( MART-1:27-35 peptide vaccine ) , tyrosinase ( tyrosinase peptide ) gp-100 ( gp100 antigen ) peptides suspended incomplete Freund 's adjuvant ( IFA ) presence two different concentration sargramostim ( GM-CSF ) . II . Define safety toxicity profile immunization protocol utilize vary concentration MART-1:27-35 , tyrosinase gp-100 peptide suspend IFA presence two different concentration GM-CSF . III . Collect preliminary data therapeutic efficacy relate parameter immune function patient stage IV malignant melanoma . OUTLINE : Patients randomize 1 3 treatment arm . ARM I : Patients receive tyrosinase peptide , MART-1:27-35 peptide vaccine , gp100 antigen admix incomplete Freund 's adjuvant subcutaneously ( SC ) day 1 week 0 , 3 , 6 , 9 , 12 , 24 . ARM II : Patients receive tyrosinase peptide , MART-1:27-35 peptide vaccine , gp100 antigen admix incomplete Freund 's adjuvant SC lower-dose sargramostim SC day 1 week 0 , 3 , 6 , 9 , 12 , 24 . ARM III : Patients receive tyrosinase peptide , MART-1:27-35 peptide vaccine , gp100 antigen admix incomplete Freund 's adjuvant SC higher-dose sargramostim SC day 1 week 0 , 3 , 6 , 9 , 12 , 24 . In arm , treatment may repeat every 3 month 18 month absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 3 year .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Freund 's Adjuvant</mesh_term>
	<criteria>Human leukocyte antigen ( HLA ) A2 positive Histologic proof stage IV malignant melanoma measurable disease Absolute neutrophil count ( ANC ) &gt; = 1500 Platelets ( PLT ) &gt; = 100,000 Alkaline phosphatase ( Alk phos ) = &lt; 3 x upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) = &lt; 3 x ULN Creatinine ( Creat ) = &lt; 1.5 x ULN Hemoglobin ( Hgb ) &gt; 9.0 Ability provide inform consent Willingness return Mayo Clinic institution followup Life expectancy &gt; = 12 week Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 2 Uncontrolled current infection Prior immunization differentiation antigen peptide Known standard therapy patient 's disease potentially curative proven capable extend life expectancy Any follow prior therapy : Chemotherapy = &lt; 4 week Mitomycin C/nitrosoureas = &lt; 6 week Immunotherapy = &lt; 4 week Biologic therapy = &lt; 4 week Radiation therapy = &lt; 4 week Radiation &gt; 25 % bone marrow Failure fully recover effect prior chemotherapy regardless interval since last treatment New York Heart Association classification III IV Seizure disorder Any following : Pregnant woman Nursing woman Women childbearing potential sexual partner unwilling employ adequate contraception ( condom , diaphragm , birth control pill , injection , intrauterine device [ IUD ] , surgical sterilization , subcutaneous implant , abstinence , etc . ) Other concurrent chemotherapy , immunotherapy , radiotherapy Active psychiatric disorder require medication ( antipsychotic ) Known central nervous system metastases carcinomatous meningitis History malignancy last 5 year exception basal cell squamous cell carcinoma skin treat local resection ( impossible predict effect study treatment , potentially dormant malignant disease ) Known immune deficiency ( patient know immune deficiency likely able mount immune response study vaccine )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>